Results Highlights

Highlights: FY16 3Q Results (As of February 6, 2017)

  • Net sales: Declined, owing to
    • Impact of optimizing our production configuration associated with restructuring initiatives in the resin business, in addition to the stronger yen, although sales were generally steady across all businesses on the whole
  • Operating income and ordinary income: Declined owing to
    • New drug licensing costs and the impact of foreign exchange movements, despite efforts to steadily improve profitability by driving growth in existing businesses and executing restructuring initiatives
  • Profit attributable to owners of parent: Declined despite
    • Lower tax expense due to the impact of changes in tax effect accounting, along with a decline in impairment loss and other factors

In the fiscal year 2016, March 31, 2017, consolidated net sales for the 3nd quarter amounted to 535.2 billion yen,
down -56.1 billion yen compared with 591.3 billion yen for the 3nd quarter of fiscal 2015. Operating income for the
3nd quarter of fiscal 2016 were 43.6 billion yen, down -11.9 billion yen compared with 55.5 billion yen for the 3nd
quarter of fiscal 2015. Ordinary income for the 3nd
quarter of fiscal 2016 amounted to 45.8 billion yen, down -
11.0 billion yen compared with 56.8 billion yen for the 3nd
quarter of fiscal 2015. Profit attributable to owners
of parent of 41.4 billion yen for the 3nd
quarter of
fiscal 2016 decreased -4.8 billion yen compared with profit
attributable to owners of parent of 46.2 billion yen in the 3nd quarter of fiscal 2015.

Total assets as of December 31, 2016, amounted to 905.8 billion yen,
increase of +824 billion yen from the end of fiscal
2015(823.4 billion yen). Shareholders´ equity was 340.5 billion yen, increase of +40.4 billion yen compared with
300.1 billion yen. Interest-bearing debt was increase of +40.4 billion yen, from 303.3 billion yen at the end of fiscal
2015 to 343.7 billion yen.

* Profit attributable to owners of parent

Financial Results